Should FDA Grant Accelerated Approval to Duchenne Muscular Dystrophy Gene Therapy?
(MedPage Today) — On May 12, independent experts narrowly recommended that the FDA grant accelerated approval to Sarepta’s new gene therapy, SRP-9001 (delandistrogene moxeparvovec), for the treatment of Duchenne muscular dystrophy (DMD). These…
Powered by WPeMatico
